{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:00:24Z","timestamp":1793520024155,"version":"4.5.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Enzyme replacement therapy (ERT) is the only approved disease-modifying treatment modality for Pompe disease, a rare, inherited metabolic disorder caused by a deficiency in the acid <jats:italic>\u03b1<\/jats:italic>-glucosidase (GAA) enzyme that catabolizes lysosomal glycogen. First-generation recombinant human GAA (rhGAA) ERT (alglucosidase alfa) can slow the progressive muscle degeneration characteristic of the disease. Still, most patients experience diminished efficacy over time, possibly because of poor uptake into target tissues. Next-generation ERTs aim to address this problem by increasing bis-phosphorylated high mannose (bis-M6P) <jats:italic>N<\/jats:italic>-glycans on rhGAA as these moieties have sufficiently high receptor binding affinity at the resultant low interstitial enzyme concentrations after dosing to drive uptake by the cation-independent mannose 6-phosphate receptor on target cells. However, some approaches introduce bis-M6P onto rhGAA via non-natural linkages that cannot be hydrolyzed by natural human enzymes and thus inhibit the endolysosomal glycan trimming necessary for complete enzyme activation after cell uptake. Furthermore, all rhGAA ERTs face potential inactivation during intravenous delivery (and subsequent non-productive clearance) as GAA is an acid hydrolase that is rapidly denatured in the near-neutral pH of the blood. One new therapy, cipaglucosidase alfa plus miglustat, is hypothesized to address these challenges by combining an enzyme enriched with naturally occurring bis-M6P <jats:italic>N<\/jats:italic>-glycans with a small-molecule stabilizer. Here, we investigate this hypothesis by analyzing published and new data related to the mechanism of action of the enzyme and stabilizer molecule. Based on an extensive collection of <jats:italic>in vitro<\/jats:italic>, preclinical, and clinical data, we conclude that cipaglucosidase alfa plus miglustat successfully addresses each of these challenges to offer meaningful advantages in terms of pharmacokinetic exposure, target-cell uptake, endolysosomal processing, and clinical benefit.<\/jats:p>","DOI":"10.3389\/fneur.2024.1451512","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T04:40:24Z","timestamp":1729226424000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease"],"prefix":"10.3389","volume":"15","author":[{"given":"Barry J.","family":"Byrne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Parenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin K.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickita","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mondick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Osman","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela","family":"Sitaraman Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Tuske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Brudvig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Weimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahseen","family":"Mozaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"ref1","article-title":"Pompe disease: glycogen storage disease type II, acid \u03b1-glucosidase (acid maltase) deficiency","volume-title":"The online metabolic and molecular bases of inherited disease","author":"Reuser","year":"2019"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ODRR.S69109","article-title":"Pompe disease: clinical perspectives","volume":"7","author":"Cabello","year":"2017","journal-title":"Orphan Drugs Res Rev"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1042\/bj0860011","article-title":"Alpha-glucosidase deficiency in generalized glycogen storage disease (Pompe's disease)","volume":"86","author":"Hers","year":"1963","journal-title":"Biochem J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/ana.20807","article-title":"Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease","volume":"59","author":"Fukuda","year":"2006","journal-title":"Ann Neurol"},{"key":"ref5","first-page":"45","article-title":"Role of autophagy in the pathogenesis of Pompe disease","volume":"26","author":"Raben","year":"2007","journal-title":"Acta Myol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1755-8417-1-6","article-title":"Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts","volume":"1","author":"Cardone","year":"2008","journal-title":"PathoGenetics"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.jpeds.2004.01.053","article-title":"Pompe disease in infants and children","volume":"144","author":"Kishnani","year":"2004","journal-title":"J Pediatr"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"100759","DOI":"10.1016\/j.gimo.2023.100759","article-title":"P687: State of play: The current landscape of newborn screening for Pompe disease in the United States","volume":"1","author":"Kho","year":"2023","journal-title":"Genet Med Open"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","article-title":"Open-label extension study following the late-onset treatment study (LOTS) of alglucosidase alfa","volume":"107","author":"van der Ploeg","year":"2012","journal-title":"Mol Genet Metab"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jimd.12272","article-title":"Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: prospective analysis from the French Pompe registry","volume":"43","author":"Semplicini","year":"2020","journal-title":"J Inherit Metab Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1007\/s00415-021-10409-9","article-title":"STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa","volume":"268","author":"Gutschmidt","year":"2021","journal-title":"J Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J Neurol"},{"key":"ref15","year":"2006"},{"key":"ref16","year":"2006"},{"key":"ref17","year":"2022"},{"key":"ref18","year":"2021"},{"key":"ref19","year":"2021"},{"key":"ref20","year":"2021"},{"key":"ref21","year":"2021"},{"key":"ref22","year":"2023"},{"key":"ref23","year":"2021"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.21037\/atm.2019.04.15","article-title":"Challenges in treating Pompe disease: an industry perspective","volume":"7","author":"Do","year":"2019","journal-title":"Ann Transl Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1172\/jci.insight.125358","article-title":"Improved efficacy of a next-generation ERT in murine Pompe disease","volume":"4","author":"Xu","year":"2019","journal-title":"JCI Insight"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.21037\/atm.2019.05.56","article-title":"Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy","volume":"7","author":"Byrne","year":"2019","journal-title":"Ann Transl Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"7962","DOI":"10.1016\/S0021-9258(18)83136-2","article-title":"Ligand interactions of the cation-independent mannose 6-phosphate receptor. The stoichiometry of mannose 6-phosphate binding","volume":"264","author":"Tong","year":"1989","journal-title":"J Biol Chem"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.ymgme.2014.12.096","article-title":"Novel recombinant human acid \u03b1-glucosidase with optimal glycosylation is significantly better than standard of care enzyme replacement for glycogen clearance in skeletal muscles of GAA knock-out mice","volume":"114","author":"Gotschall","year":"2015","journal-title":"Mol Genet Metab"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"6780","DOI":"10.1074\/jbc.M404008200","article-title":"Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor","volume":"280","author":"Moreland","year":"2005","journal-title":"J Biol Chem"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"100769","DOI":"10.1016\/j.jbc.2021.100769","article-title":"Endolysosomal N-glycan processing is critical to attain the most active form of the enzyme acid alpha-glucosidase","volume":"296","author":"Selvan","year":"2021","journal-title":"J Biol Chem"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1021\/bc1005416","article-title":"Strategies for neoglycan conjugation to human acid alpha-glucosidase","volume":"22","author":"Zhou","year":"2011","journal-title":"Bioconjug Chem"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1124\/jpet.123.001593","article-title":"Increasing enzyme Mannose-6-phosphate levels but not Miglustat Coadministration enhances the efficacy of enzyme replacement therapy in Pompe mice","volume":"387","author":"Anding","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e102092","DOI":"10.1371\/journal.pone.0102092","article-title":"The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease","volume":"9","author":"Khanna","year":"2014","journal-title":"PLoS One"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.molimm.2014.10.022","article-title":"Enhanced recognition of plasma proteins in a non-native state by complement C3b. A possible clearance mechanism for damaged proteins in blood","volume":"64","author":"Ramadass","year":"2015","journal-title":"Mol Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ddtec.2021.02.003","article-title":"Recent advances in CHO cell line development for recombinant protein production","volume":"38","author":"Tihanyi","year":"2020","journal-title":"Drug Discov Today Technol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1038\/mt.2014.138","article-title":"A chaperone enhances blood alpha-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy","volume":"22","author":"Parenti","year":"2014","journal-title":"Mol Ther"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drudis.2010.08.017","article-title":"Iminosugars past, present and future: medicines for tomorrow","volume":"16","author":"Horne","year":"2011","journal-title":"Drug Discov Today"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/0883073809344222","article-title":"Long-term miglustat therapy in children with Niemann-pick disease type C","volume":"25","author":"Patterson","year":"2010","journal-title":"J Child Neurol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ymgme.2009.12.006","article-title":"Miglustat in adult and juvenile patients with Niemann-pick disease type C: long-term data from a clinical trial","volume":"99","author":"Wraith","year":"2010","journal-title":"Mol Genet Metab"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3324\/haematol.2009.008078","article-title":"Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project","volume":"94","author":"Giraldo","year":"2009","journal-title":"Haematologica"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","article-title":"Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease","volume":"27","author":"Elstein","year":"2004","journal-title":"J Inherit Metab Dis"},{"key":"ref42","year":"2016"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10545-012-9523-9","article-title":"Miglustat-induced intestinal carbohydrate malabsorption is due to the inhibition of alpha-glucosidases, but not beta-galactosidases","volume":"35","author":"Amiri","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"ref44","year":"2014"},{"key":"ref45","year":"2014"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s00415-023-12096-0","article-title":"Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I\/II study (ATB200-02)","volume":"271","author":"Byrne","year":"2024","journal-title":"J Neurol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.ymgme.2021.11.158","article-title":"Plasma total GAA protein PK profiles differ between cipaglucosidase alfa\/miglustat and alglucosidase alfa","volume":"135","author":"Johnson","year":"2022","journal-title":"Mol Genet Metab"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/mt.2009.53","article-title":"The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts","volume":"17","author":"Porto","year":"2009","journal-title":"Mol Ther"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"107042","DOI":"10.1016\/j.ymgme.2022.107042","article-title":"Long-term follow-up of cipaglucosidase alfa\/miglustat in ambulatory patients with Pompe disease: an open-label phase I\/II study (ATB200-02)","volume":"138","author":"Byrne","year":"2023","journal-title":"Mol Genet Metab"},{"key":"ref50","year":"2023"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1124\/jpet.123.002014","article-title":"Response to: increasing enzyme mannose-6-phosphate levels but not miglustat coadministration enhances the efficacy of enzyme replacement therapy in Pompe mice","volume":"389","author":"Brudvig","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1124\/jpet.123.002080","article-title":"Response to comments on \"Increasing enzyme Mannose-6-phosphate levels but not miglustat coadministration enhances the efficacy of enzyme replacement therapy in Pompe mice\"","volume":"389","author":"George","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.3390\/ijms22094381","article-title":"Biomarkers in glycogen storage diseases: an update","volume":"22","author":"Molares-Vila","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"286","DOI":"10.21037\/atm.2019.06.60","article-title":"Diagnostic tools in late onset Pompe disease (LOPD)","volume":"7","author":"Musumeci","year":"2019","journal-title":"Ann Transl Med"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","article-title":"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial","volume":"20","author":"Schoser","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"107971","DOI":"10.1016\/j.ymgme.2023.107971","article-title":"Effect size analysis of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL","volume":"141","author":"Mozaffar","year":"2024","journal-title":"Mol Genet Metab"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1007\/s00415-024-12236-0","article-title":"104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)","volume":"271","author":"Schoser","year":"2024","journal-title":"J Neurol"},{"key":"ref58","year":"2022"},{"key":"ref59","year":"2022"},{"key":"ref60","year":"2022"},{"key":"ref61","year":"2022"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","article-title":"Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naive and alglucosidase alfa-treated patients with late-onset Pompe disease: a phase 1, open-label, multicenter, multinational, ascending dose study","volume":"29","author":"Pena","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3390\/biom13081227","article-title":"Therapeutic role of pharmacological chaperones in lysosomal storage disorders: a review of the evidence and informed approach to reclassification","volume":"13","author":"Keyzor","year":"2023","journal-title":"Biomol Ther"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaneurol.2023.0552","article-title":"Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 97 weeks: a phase 3 randomized clinical trial","volume":"80","author":"Kishnani","year":"2023","journal-title":"JAMA Neurol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.jval.2023.03.195","article-title":"Late-onset Pompe disease patients treated with avalglucosidase alfa show favorable results compared with cipaglucosidase alfa plus miglustat: indirect treatment comparison","volume":"26","author":"Roberts","year":"2023","journal-title":"WORLD"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"107046","DOI":"10.1016\/j.ymgme.2022.107046","article-title":"Indirect treatment comparison of three enzyme replacement treatments for late-onset Pompe disease: a network meta-analysis with patient-level and aggregate data","volume":"138","author":"Castelli","year":"2023","journal-title":"Mol Genet Metab"}],"updated-by":[{"DOI":"10.3389\/fneur.2024.1540452","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000}}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1451512\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T14:06:58Z","timestamp":1735308418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1451512\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":67,"alternative-id":["10.3389\/fneur.2024.1451512"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1451512","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fneur.2024.1540452","asserted-by":"object"}]},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"article-number":"1451512"}}